The medical recommendations for adult LCH have been published in Orphanet Journal of Rare Diseases.

More ...
An­nu­al in­ter­na­tio­nal con­fe­rence of sci­en­tists, pa­tho­lo­gists and cli­ni­ci­ans discussing histiocytoses and their backgrounds. More ...
An International Community of Professionals Dedicated to Research and Treatment More ...
PubMed comprises more than 20 million citations for biomedical literature from MEDLINE, life science journals, and online books. More ...

European Union Clinical Trials Register of the European Medicines Agency

More ...

European Clinical Trials Database of the European Medicines Agency

More ...
Rare diseases in EU
Why do rare diseases need specific EU support? More ...
Euro Histio Net has received funding from the European Union, in the framework of the Public Health Programme. More ...

Central nervous system involvement

Author(s): Euro Histio Net Work Group for LCH Guidelines for adults (see introduction page), Created: 2012/07/26, last update: 2013/08/18

Tumorous lesions

These lesions are most frequently observed in the hypothalamic-pituitary region. The tumor size ranges from discrete thickening of the pituitary stalk to larger tumors. Parenchymal, meningeal or choroid plexus lesions occur less frequently [Grois et al 2010].

In addition to hormone replacement isolated cerebral tumors should be treated with irradiation or chemotherapy and pituitary/hypothalamic lesions with chemotherapy. Multifocal brain lesions or single brain lesions with multi system disease need to be treated with chemotherapy. The most suitable drugs are Cladribine or Cytarabine as described above. (Grade C2 *)

Neurodegerative LCH

Non-tumorous MRI findings of the cerebellum, and/or brain stem are histopathologically different than the typical LCH mass lesions. The neurodegenerative lesions lack CD1a+ histiocytes and have infiltrating CD8+ lymphocytes. [Grois et al 2005]. Some of these patients show no symptoms, others have clinical signs ranging from subtile tremor, dysarthria, dysphagia, and motor spasticity to pronounced ataxia, behavioral disturbances and severe psychiatric disease.
Retinoic acid and intravenous immunoglobulin may stabilize such patients [Idbaih et al 2004; Imashuku et al 2008]. Improvement with infliximab has been observed in one case [Chohan et al 2012]. Cytarabine with or without Vincristine provided improvement in 5/8 patients of which 4/8 remained stable over more than 7 years of follow-up and one relapsed but is improved after treatment with intravenous Methotrexated. Patients who responded to Cytarabine/Vincristine had symptoms for less than 18 months before starting treatment [Allen et al 2010; Allen 2010]. Thus early onset of Cytarabine is recommended as first line therapy, but for any case of neurodegenerative LCH we suggest discussion with the reference centre for your country. (Grade C1*)

* Grades of recommendation see here.


[Grois et al 2010] Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, Nanduri V, Prosch H, Prayer D, Histiocyte Society CNS LCH Study Group: Central nervous system disease in Langerhans cell histiocytosis. The Journal of pediatrics 2010, 156: 873-81, 881.e1 [PMID: 20434166]

[Grois et al 2005] Grois N, Prayer D, Prosch H, Lassmann H, CNS LCH Co-operative Group: Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain : a journal of neurology 2005, 128(Pt 4): 829 [PMID: 15705614]

[Idbaih et al 2004] Idbaih A, Donadieu J, Barthez MA, Geissmann F, Bertrand Y, Hermine O, Brugières L, Genereau T, Thomas C, Hoang-Xuan K: Retinoic acid therapy in . Pediatric blood & cancer 2004, 43: 55 [PMID: 15170890]

[Imashuku et al 2008] Imashuku S, Okazaki N',Nakayama M, Fujita N, Fukuyama T, Koike K, Minato T, Kobayashi R, Morimoto A, Japan LCH Study Group: Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatric blood & cancer 2008, 50: 308 [PMID: 17458874]

[Chohan et al 2012] Chohan G, Barnett Y, Gibson J, Reddel SW, Barnett MH: Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. Journal of neurology, neurosurgery, and psychiatry 2012, 83: 573 [PMID: 21856693]

[Allen et al 2010] Allen CE, Flores R, Rauch R, Dauser R, Murray JC, Puccetti D, Hsu DA, Sondel P, Hetherington M, Goldman S, McClain KL: Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatric blood & cancer 2010, 54: 416 [PMID: 19908293]

[Allen 2010] Allen CE: Personal communication about. In: Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside 2010